Microbix welcomes European revocation of Inguran sperm patent

Microbix Biosystems (TSX:MBX) has welcomed a decision by the European Patent Office revoking a patent on frozen-sperm/XY held by Inguran LLC, doing business as Sexing Technologies LLC and XY LLC. The patent relates to the use of cryopreservation technology for sperm cells sorted into sex-selected populations. Microbix participated in the opposition proceedings through direct submission [...]

Novadaq Q1 revenue beats consensus

Revenue for Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) jumped 103% to $4.8 million in the first quarter this year, beating analysts’ consensus of $4.6 million, on increased sales of systems and procedure kits across both of its commercial SPY Imaging businesses: SPY Elite and FIREFLY. The combined installed base of SPY technology in the U.S. now exceeds [...]

Cynapsus nominates Molinoff and Picone as directors

Cynapsus Therapeutics (TSX-V:CTH) has nominated Dr. Perry Molinoff, former Vice Provost of the University of Pennsylvania, and Dr. Thomas Picone, a seasoned senior pharma executive, to join the board at the annual meeting on May 30, 2012. Cynapsus president and CEO Anthony Giovinazzo will also join the board, replacing David Hill, who is stepping down. [...]

Response Biomedical names Jeffrey Purvin as CEO

Response Biomedical (TSX:RBM) has named Jeffrey Purvin as CEO, effective yesterday. Mr. Purvin has over 30 years of experience marketing both consumer and medical products. Most recently, he was chairman and CEO of Calibra Medical, where he and his team developed and gained FDA clearance for a unique insulin delivery device, successfully positioning the company [...]

TearLab adds reimbursement update section to website

For Medicare patients, testing with TearLab’s (NASDAQ:TEAR; TSX:TLB) Osmolarity System is reimbursed in every state by CMS.  But, private insurance reimbursement policy is not uniform.  It depends on provider contracts and varies from state to state, payer to payer and even policy to policy. As CEO Elias Vamvakas told investors on TearLab’s quarterly conference call [...]

NovaBay’s Aganocide out-performed antibiotics in study

NovaBay Pharmaceuticals (AMEX:NBY) says key study data demonstrating that development of resistance to its lead Aganocide compound, NVC-422, is highly unlikely for a variety of infectious organisms, including methicillin-resistant S. aureus (MRSA), compared with traditional antibiotics, were published in the May 2012 issue of Antimicrobial Agents and Chemotherapy, the journal for the American Society for [...]

Health Canada okays Sernova trial of Cell Pouch

Sernova (TSX-V: SVA) has received Health Canada approval to conduct a human clinical trial assessing the safety and efficacy of its Cell Pouch with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The Phase 1/2 study, with up to 20 patients, will be conducted in collaboration with Dr. James Shapiro at the University of Alberta [...]

TearLab: pre-operative osmolarity study on LASIK outcomes to be presented at ARVO 2012

TearLab (NASDAQ:TEAR; TSX:TLB) says that a paper reporting on a multi-site refractive surgery center study designed to determine if pre-operative tear osmolarity levels relate to visual acuity outcomes following LASIK surgery will be presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida. The presentation, entitled “Pre-surgical Hyperosmolarity [...]

Vaxil encouraged by cancer vaccine data

Closely held Vaxil BioTherapeutics of Israel is encouraged by the immune response that its ImMucin cancer vaccine is generating in an ongoing Phase 1/2 clinical trial in patients with multiple myeloma. “We’ve managed to get a robust MUC1 specific immune response from two important immune cells—CD4+ T-cells and CD8+ T-cells—in all patients,” founder and CEO [...]

ROTH ups Conceptus price target

In the wake of Conceptus (NASDAQ:CPTS) and Hologic (NASDAQ:HOLX) settling a patient infringement suit, ROTH Capital Partners has raised its price target on “buy-rated” Conceptus to $22 from $16. The stock touched a 52-week high of $20.20 earlier today before easing to $19.30, up $4.12, in heavier than normal turnover. Under the settlement, Hologic will [...]

« Previous Page — Next Page »